Senseonics Reports 118% Revenue Growth to $14.5 Million in Latest Quarter

Senseonics Holdings, Inc. reported significant financial growth in its latest quarterly results, with total revenue reaching $14.5 million for the three months ended June 30, 2026, compared to $6.6 million for the same period in 2025. This represents a 118% increase, primarily driven by increased sales in the U.S. market, particularly through its consignment program and the demand for its 365-day continuous glucose monitoring (CGM) product. The company also noted a shift in revenue generation following the termination of its commercialization agreement with Ascensia, which previously accounted for a substantial portion of its sales.

The company's gross profit for the second quarter of 2026 was $8.6 million, yielding a gross margin of 59.1%, up from 46.9% in the prior year. This improvement is attributed to favorable margins on the new 365-day product, higher sales through the consignment network, and the elimination of revenue-sharing costs associated with Ascensia. However, Senseonics reported an operating loss of $36.0 million for the quarter, significantly higher than the $14.3 million loss recorded in the same quarter of 2025, largely due to increased research and development expenses and a substantial rise in selling, general, and administrative costs.

For the six months ended June 30, 2026, total revenue was $26.2 million, compared to $12.9 million in the same period of 2025, marking a 102% increase. The company incurred a net loss of $69.0 million for the first half of 2026, compared to a loss of $28.8 million in the prior year. The increase in losses is attributed to higher operational costs associated with the transition of commercialization activities back to the company and the ramp-up of its product development initiatives, including the Gemini pivotal study.

Operationally, Senseonics has expanded its market presence by transitioning commercialization responsibilities for its Eversense products from Ascensia back to itself, effective January 1, 2026. The company has also established new subsidiaries in Europe to support local operations and distribution, enhancing its ability to market its products directly. As of June 30, 2026, Senseonics reported cash, cash equivalents, and marketable securities totaling $142.7 million, providing a solid liquidity position to support ongoing operations and strategic initiatives.

Looking ahead, Senseonics aims to leverage its direct sales capabilities and expand its consignment arrangements to drive further revenue growth. The company anticipates that its existing cash reserves, along with projected cash flows from operations, will be sufficient to fund its activities through at least 2028. However, it remains open to accessing additional funding through debt or equity markets to enhance its capital structure and support future growth initiatives.